BSE filing, NSE: FERVENTSYN. Summary written from the filing by ALFA Finder's alert engine.
Fervent Synergies Ltd: key numbers
- Share price
- ₹16.50
- Market cap
- ₹82.50 Cr
- Revenue (annual)
- ₹16.35 Cr
- Net profit (annual)
- ₹3.82 Cr
- P/E (TTM)
- 22.7×Sector 19.7×
- Promoter holding
- 74.75%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fervent Synergies Ltd
All →Fervent Synergies Board Meeting Date
Fervent Synergies Limited has scheduled a board meeting on October 29, 2026. The board will consider and approve unaudited financial results for the September quarter.
Fervent Synergies Annual General Meeting
Fervent Synergies Limited conducted its 17th Annual General Meeting on August 27, 2026. Shareholders approved the audited financial statements and the re-appointment of Director Mr. Karan Vijay Thakkar.
Fervent Synergies Annual Report
Fervent Synergies Ltd has submitted its Annual Report for the financial year 2025-26. This filing includes the notice for the 17th Annual General Meeting.
Fervent Synergies Annual General Meeting
Fervent Synergies Ltd scheduled its 17th Annual General Meeting for September 27, 2026. The register of members will close from August 21 to August 27, 2026.
Fervent Synergies Q1 FY27 Results: Net Profit ₹0.2 Cr, Down 50.0% YoY
Fervent Synergies Ltd reported revenue from operations of ₹0.7 Cr (+0.0% YoY) and net profit of ₹0.2 Cr (-50.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.2 Cr · -50.0% YoY
Fervent Synergies Board Meeting Date
Fervent Synergies Ltd will hold a Board meeting on 23 July 2026 to approve its Q1‑2026 results. The notice sets a trading window closure from 1 July.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.